Corvus Pharmaceuticals Cash Flow Statement
NASDAQ: CRVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.52+0.31 (+3.04%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corvus Pharmaceuticals free cash flow
In fiscal 2025, Corvus Pharmaceuticals generated -$32.8 million of operating cash flow and spent $174,000 on capital expenditures. That left free cash flow of -$33.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Corvus Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20212022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -15.28M | -62.29M | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M | -46.94M | -55.66M | -36.38M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 105.00K | 85.00K | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K |
| Stock-Based Compensation | 5.33M | 3.00M | 2.15M | 2.69M | 4.23M | 5.75M | 7.35M | 7.13M | 6.23M | 3.83M |
| Change in Working Capital | 850.00K | -530.00K | -459.00K | 992.00K | -2.18M | 1.30M | 80.00K | -1.27M | 1.51M | 808.00K |
| Operating Cash Flow | -32.80M | -25.42M | -23.93M | -27.02M | -36.72M | -34.78M | -37.32M | -40.99M | -46.21M | -27.86M |
| Capital Expenditures | -174.00K | — | -34.00K | -269.00K | -5.00K | -76.00K | -25.00K | -355.00K | -266.00K | -2.20M |
| Investing Cash Flow | -7.80M | -27.48M | 15.54M | -23.28M | 21.56M | 44.77M | 3.25M | -30.19M | 84.83M | -42.56M |
| Financing Cash Flow | 36.43M | 49.03M | 7.86M | 0 | 62.16M | 1.31M | 24.00K | 65.27M | 1.44M | 71.36M |
| Net Change in Cash | -4.16M | -3.88M | -539.00K | -50.30M | 47.00M | 11.30M | -34.04M | -5.91M | 40.06M | 945.00K |
| Free Cash Flow | -32.97M | -25.42M | -23.97M | -27.29M | -36.72M | -34.85M | -37.35M | -41.34M | -46.48M | -30.06M |
This table shows 10 annual periods of Corvus Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CRVS's reporting calendar. What is a cash flow statement?